Alexion Of U.S. Applies For Japan Approval Of Soliris
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Alexion Pharmaceuticals has applied in Japan for approval of its Soliris (eculizumab) for treating paroxysmal nocturnal hemoglobinuria blood disorders. Alexion wants to provide the treatment to Japanese who have the rare blood disorder that destroys red cells. The company already has clearance for its PNH treatment in several other countries, including the United States. (Click here for more